Alaunos Therapeutics, Inc. — Director's Dealing 2021

May 7, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ZIOPHARM ONCOLOGY INC (ZIOP)
CIK: 0001107421
Period of Report: 2021-03-04

Reporting Person: Huang James (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-04	Common Stock	A	8333	$0.00	Acquired	8333	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-04	Stock Option (right to buy)	$4.31	A	62500	Acquired	2031-03-03	Common Stock (62500)	Direct

Footnotes

F1: The shares will vest on 5/19/2021.

F2: 1/3rd of the shares underlying this option will vest on 4/4/2021, 5/4/2021 and 5/19/2021.